Dr. Fallah[/caption]
Mahdi Fallah, MD, PhD
Study and Group Leader
Risk Adapted Prevention (RAD) Group
Division of Preventive Oncology
National Center for Tumor Diseases (NCT)
German Cancer Research Center (DKFZ)
Heidelberg, Germany
MedicalResearch.com: What is the background for this study?
Response: Breast cancer is a significant public health problem, being the most commonly diagnosed cancer and the second leading cause of cancer death in women in the US. Breast cancer screening from age 50 has been associated with a reduction in mortality and is recommended by the US Preventive Services Task Force. However, there is a significant disparity in mortality rates between Black and White individuals, with Black women having a higher death rate, especially before age 50. The current one-size-fits-all policy for breast cancer screening may not be equitable or optimal, and risk-adapted starting ages of screening based on known risk factors, such as race and ethnicity, may be recommended to optimize the benefit of screening. Our study aimed to provide evidence for a risk-adapted starting age of screening by race and ethnicity.
Dr. Hurwitz[/caption]
Lauren Hurwitz, PhD
Postdoctoral Fellow
Division of Cancer Epidemiology & Genetics
National Cancer Institute
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Prior studies have demonstrated that frequent (i.e., daily or near daily) use of aspirin is associated with a lower risk of developing ovarian cancer. We sought to determine if this risk reduction is also observed for individuals with greater genetic susceptibility to ovarian cancer, who may benefit more from preventive interventions.
Our study found that individuals who took aspirin frequently had a lower risk of ovarian cancer, regardless of whether they had higher or lower genetic susceptibility to ovarian cancer.
Response: We were broadly interested in discovering instances of bacterial genes that have been acquired by diverse animal genomes over millions of years of evolution by the process of horizontal gene transfer (HGT). Since these events are quite rare and most previous discoveries have been serendipitous, we developed computational methods to identify genes acquired by HGT in animals. One of the exciting discoveries from our work was that vertebrate IRBP appeared to have originated in bacteria and is now a critical component of the vertebrate visual cycle, so this paper focuses on that one discovery.
IRBP or interphotoreceptor retinoid binding protein is an important protein present in the space between two major cell types in our eyes, photoreceptor cells and RPE cells. Our ability to see involves an intricate set of steps where light is first sensed by causing a change (isomerization) in the chemical structure of molecules in the eye called retinoids. This sensing of light occurs in our photoreceptor cells. Following this change in the chemical structure, the retinoid needs to be recycled back to the chemical structure that can again sense light. This recycling occurs in RPE cells. IRBP performs the essential function of shuttling retinoids between the photoreceptors and the RPE cells, which allows the cycle of sensing and regeneration to work. Supporting its importance, mutations in IRBP (also known as retinol binding protein 3 or RBP3) can cause several severe human eye diseases.
MedicalResearch.com Interview with: [caption id="attachment_60303" align="alignleft" width="150"] Dr. Zafar Janjua[/caption] Naveed Zafar Janjua, MBBS, MSc, DrPH Executive Director, Data and Analytic Services BC Centre...
Dr. Esteban McCabe[/caption]
Sean Esteban McCabe, PhD
Director, Center for the Study of Drugs, Alcohol, Smoking and Health
Department of Health Behavior and Biological Sciences
University of Michigan School of Nursing
Ann Arbor, MI
MedicalResearch.com: What is the background for this study?
Response: Prescription stimulant therapy for ADHD helps millions of people, including in my own family, and students, friends and colleagues. It's critical to balance the need for access to these medications while reducing the risk for misuse. This is more important than ever now because there have been recent increases in the prescribing of stimulant therapy for ADHD. There is a need to understand the prevalence of stimulant therapy for ADHD and prescription stimulant misuse in U.S. middle and high schools.
Dr. Buckley[/caption]
Rachel Buckley, PhD
Assistant Professor
Department of Neurology
Massachusetts General Hospital/Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: While a fair amount of studies have focused on the effects of menopause and hormone therapy on risk of dementia, far fewer studies have tested their association with the biology of Alzheimer’s disease, namely amyloid and tau. This is critical to know given that it still remains unclear what might be the driving mechanism of the menopause transition on risk for dementia. This is what our study set out to investigate.
This study is one of the first to report a link between women’s age at menopause and tau in the brain, which we measured with positron emission tomography neuroimaging. We found that in multiple areas of the brain that tend to be most likely to show higher tau in women than men, women with earlier age at menopause and elevated levels of amyloid showed higher levels of tau than those who reported an average age at menopause (~50 years in the United States). Women who reported premature menopause (<40 years at menopause onset) exhibited a much higher risk of tau in the brain. This supports the notion that longer exposure to estrogen throughout life might be protective against Alzheimer’s disease.
Dr. Hatoum[/caption]
Alexander S. Hatoum, PhD
Research Assistant Professor
Institute for Behavioral Genetics
Washington University in St. Louis
MedicalResearch.com: What is the background for this study?
Response: It is well known that someone with one substance use disorder will have another sometime in their lifetime or concurrently. Further, individuals that do manifest two or more substance use disorders in their lifetime have the most morbid conditions. However, research often ignores the comorbidity and focuses on diagnosis of one substance use disorder at a time (i.e. opioid use disorder or alcohol use disorder). We set out to identify the biology behind the cross-substance liability.
Dr. Potter[/caption]
MedicalResearch.com Interview with:
Kelly Potter, PhD, RN, CNE
T32 Postdoctoral Scholar
CRISMA Center, Department of Critical Care Medicine
University of Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: While it is well-recognized that survivors of critical illness often experience persistent problems with mental, cognitive, and physical health, very little is known about how these problems (collectively known as post-intensive care syndrome (PICS)) affect resumption of meaningful activities, such as driving.
Dr. Jonathan Silverberg[/caption]
Jonathan Silverberg, MD, PHD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Lebrikizumab was previously shown to be safe and effective as a treatment for moderate-severe atopic dermatitis in a phase 2 study. These Phase 3 randomized placebo-controlled trials are the largest studies to date of lebrikizumab in AD. They showed that lebrikizumab was safe and highly effective for the treatment of moderate-severe atopic dermatitis. These studies will hopefully support the approval of lebrikizumab in the United States later this year.
Dr. D'Orsogna[/caption]
Maria-Rita D'Orsogna Ph.D.
Professor, Mathematics
California State University, Northridge
Adjunct Associate Professor
Department of Computational Medicine at UCLA
MedicalResearch.com: What is the background for this study?
Response: Drug overdose deaths have been increasing in the USA for the past two decades. A ‘third wave’ of overdose fatalities started in 2013, with a shift from prescription opioids towards synthetic ones, in particular illicit fentanyl.
To examine trends in drug overdose deaths by gender, race and geography in the United States during the period 2013-2020, we used an epidemiological database provided by the Centers for Disease Control and Prevention, extracting rates by race and gender in all 50 states plus the District of Columbia. We considered the impact of four main drug categories psychostimulants with addiction potential such as methamphetamines; heroin; prescription opioids and synthetic opioids such as fentanyl and its derivatives.
Dr. Koh[/caption]
Andrew Y. Koh, M.D.
Associate Professor, Pediatrics and Microbiology
University of Texas Southwestern Medical Center
Director of Pediatric Cellular and ImmunoTherapeutics Program
University of Texas Southwestern Medical Center and Children's Health
MedicalResearch.com: What is the background for this study?
Response: We asked the basic question how does a bacteria in your gut help your immune system fight a cancer outside the gut (extraintestinal tumor). Based on work that our group and others have published in the infectious diseases, microbiology, and inflammation fields, we knew that certain conditions (e.g. inflammation, infection) promote gut microbiota to move from the gut to the mesenteric lymph nodes. So we hypothesized that immune checkpoint therapy (which essentially induces inflammation to promote tumor killing) might induce gut microbiota translocation to the mesenteric lymph nodes and that this might be the first step by which gut bacteria can engage with host immune cells.
Dr. Mosley[/caption]
Jonathan Mosley, MD, PhD
Associate Professor
Division of Clinical Pharmacology
Departments of Internal Medicine and Biomedical Informatics
Vanderbilt University Medical Center
MedicalResearch.com: What is the background for this study?
Response: Prostate cancer is an important source of morbidity and mortality among men. Earlier detection of disease is essential to reduce these adverse outcomes. Prostate cancer is heritable, and many single nucleotide polymorphisms (SNPs) associated with disease risk have been identified. Thus, there is considerable interest in using tools such as polygenic risk scores, which measure the burden of genetic risk variants an individual carries, to identify men at elevated risk of disease.
Dr. Tsirigos[/caption]
Aristotelis Tsirigos, Ph.D.
Professor of Medicine and Pathology
Co-director, Precision Medicine
Director, Applied Bioinformatics Laboratories
Dr. Hulstrøm[/caption]
Veronica Hulstrøm MD, PhD
Senior Director
Clinical Project Lead for RSV Older Adults
GSK
MedicalResearch.com: What is the background for this study?
Response: The AReSVi-006 phase III trial is designed to investigate the efficacy and safety of GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. The phase III trial is a randomized, placebo-controlled, double-blind, international trial with 24,966 participants who received either the investigational vaccine or placebo.
Hyuna Sung, PHD
Senior Principal Scientist, Cancer Surveillance Research
American Cancer Society
Kennesaw, GA 30144
Prof. Myeong-Ki Hong[/caption]
MedicalResearch.com Interview with:
Myeong-Ki Hong, MD PhD
Professor of Cardiology
Yonsei University College of Medicine
Severance Cardiovascular Hospital
Seoul, Korea
MedicalResearch.com: What is the background for this study?
Response: The background of this study was to compare the long-term clinical outcomes between the two distinct strategies regarding statin intensity in patients with coronary artery disease (CAD).
One is to titrate statin intensity to meet a target low-density lipoprotein cholesterol (LDL-C) level (treat-to-target strategy), the other is to maintain high-intensity statin without a target goal (high-intensity statin strategy).
Dr. Roca[/caption]
Anna Roca PhD
MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine
Fajara, The Gambia
MedicalResearch.com: What is the background for this study?
Response: Context specific interventions are needed to decrease the high burden of severe neonatal morbidity and mortality in sub-Saharan Africa. Severe bacterial infections are a main cause of neonatal mortality in the continent. Oral intra-partum azithromycin is a cheap intervention easily scalable. Before embarking on this trial, we conducted a proof-of-concept trial that showed the intervention reduced maternal and neonatal bacterial carriage of the most prevalent bacteria causing neonatal sepsis in the continent.
Dr. Gaudino[/caption]
Mario FL Gaudino, MD, PhD, MSCE, FEBCTS, FACC, FAHA
Stephen and Suzanne Weiss Professor in Cardiothoracic Surgery (II)
Assistant Dean for Clinical Trials
Professor of Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School
Director of the Joint Clinical Trials Office (JCTO)
Director of Translational and Clinical Research, Department of Cardiothoracic Surgery
Chair Coronary Artery Task Force, European Association for Cardio-Thoracic Surgery
Weill Cornell Medicine | NewYork – Presbyterian Hospital
Department of Cardiothoracic Surgery
MedicalResearch.com: What is the background for this study?
Response: It is well-documented that women undergoing CABG have higher mortality and morbidity when compared with men. They are referred to surgery later than men, with more cardiovascular risk factors than men, and present more frequently with heart failure or in non-elective settings. However, overall CABG outcomes have improved over time, and so we sought to evaluate national trends in outcomes specifically in women.
Dr. MIller[/caption]
Dr Jessica Miller, PhD
Murdoch Children’s Researcher and
Professor David Burgner,
Murdoch Children’s Group Leader, Infection and Immunity
Murdoch Children’s Research Institute
Royal Children's Hospital
Victoria Australia
MedicalResearch.com: What is the background for this study?
Response: Early reports following the initial COVID-19 lockdowns showed huge variation in changes to preterm birth and stillbirth rates, deeming it difficult to understand the pattern worldwide. It was uncertain if the observed variations were due to differences in study design and methodology, immediate impacts of lockdowns or changes in health service utilization. Previous reports from single populations or facilities were unlikely to be representative of the population and could not be compared across populations. Lockdowns affected health, social and economic factors that could lead to reductions in preterm birth rates. Changes in hygiene practices and abruptions to traffic following lockdown led to alterations in non-COVID infections and air pollution, which are known to trigger inflammation and contribute to preterm birth.
Given the uncertainty in the earlier reports, we aimed to conduct a rigorous, standardised analysis using high-quality, total-population data from across the world in order to summarize and compare rates across countries. Our large global study included 52 million births between 2015-2020 from 26 countries and represents one of the first large-scale analyses of birth outcomes during the early months of COVID-19.
MedicalResearch.com Interview with: [caption id="attachment_60090" align="alignleft" width="200"] Dr. Leyba[/caption] Katarina Leyba, MBA, MD University of Colorado School of Medicine MedicalResearch.com: What is the background...
MedicalResearch.com Interview with: Siri Choragudi Medical Student University of Miami Gil Yosipovitch, MD Professor and Stiefel endowed Chair of Medical Dermatology at the Dr Phillip...
Dr. Wadhera[/caption]
Rishi K. Wadhera, MD, MPP, MPhil
Section Head, Health Policy and Equity,
Richard A. and Susan F. Smith Center for Outcomes Research
Associate Program Director
Cardiovascular Medicine Fellowship at Beth Israel Deaconess Medical Center
Assistant Professor of Medicine,
Harvard Medical School
@rkwadhera
MedicalResearch.com: What is the background for this study?
Response: High and rising prescription drug costs in the United States contribute to medication non-adherence and financial strain among adults with cardiovascular risk factors or disease. As a result, addressing prescription drug costs in patients with chronic conditions has become a national priority.
In response to these growing concerns, federal policymakers passed the Inflation Reduction Act on August 16, 2022, which aims to address high out-of-pocket drug costs for adults enrolled in Medicare Part D, by placing a $2000 annual cap on out-of-pocket prescription drug costs and expanding eligibility for full low-income subsidies to individuals that reduce deductible costs and prescription copayments (among several other provisions). It is unclear how these provisions will affect Medicare beneficiaries with cardiovascular risk factors and/or conditions.
Dr. Stevermer[/caption]
James Stevermer, M.D., M.S.P.H.
Vice chair for clinical affairs
Professor of family and community medicine
University of Missouri
Medical director of MU Health Care Family Medicine–Callaway Physicians,
Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.
MedicalResearch.com: What is the background for this study?
Response: Genital herpes is a common sexually transmitted infection (STI) that unfortunately has no cure and cannot accurately be detected in people who do not have signs of the condition. The current screening tests have limitations and there is a high chance that test results will say a person has the condition when they do not. In addition, the available treatments are focused on managing symptoms and preventing the condition from reoccurring. As a result, the Task Force concluded that the harms of screening outweigh the benefits.
MedicalResearch.com Interview with: Dr. Nora Volkow MD Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism Dardo Tomasi PhD Laboratory of Neuroimaging, National...
Michael Liu[/caption]
Michael Liu, MPhil
Rhodes Scholar,MPhil in Evidence-Based Social Intervention and Policy Evaluation.
Harvard Medical School
Boston, Massachusetts
MedicalResearch.com: What is the background for this study?
Response: Over the past few decades, research has shown that lesbian, gay, and bisexual (LGB) individuals have worse health outcomes and face unique challenges related to their experiences and costs of care. These disparities are driven by “minority stress” associated with belonging to a marginalized group. Such stressors erode health through a range of structural and interpersonal forces, including employment discrimination, family rejection, and internalized stigma
One early analysis established national baseline estimates for LGB health outcomes using 2013-2014 National Health Interview Survey (NHIS) data. Since then, there have been substantial shifts in social policy and public opinion that may have differentially affected sexual minority subgroups. The US Supreme Court decision in Obergefell v. Hodges guaranteed the constitutional right to same-sex marriage across all states. Over the last decade, states have expanded rights and protections for LGB populations related to employment and housing discrimination, sexual orientation conversion efforts, HIV criminalization, and religious exemptions. Public support for LGB-related issues has also been increasing with more representation in media, uptake of LGB-affirming policies, and advocacy efforts.
No studies have assessed national trends in health status or healthcare access among specific sexual minority subgroups amid the rapidly shifting sociocultural and policy landscape. Thus, we sought out to evaluate if and how health status and healthcare access have changed between 2013 and 2018 in the US among LGB adults, and whether differences relative to their heterosexual counterparts have changed over time.
Dr. Itagaki[/caption]
Shinobu Itagaki, MD, MSc
Assistant Professor
Cardiovascular Surgery
Icahn School of Medicine at
Mount Sinai, New York, NY
MedicalResearch.com: What is the background for this study? Were the transplants from a single donor?
Response: The heart transplantation is the gold standard therapy for end-stage heart failure patients. As the kidney is affected by the heart function, it is common that the heart transplant candidates have some degree of kidney dysfunction as well. In these cases, the candidates are considered for simultaneous heart and kidney transplantation from a same donor. Unlike isolated heart transplantation, where the indication and benefits have been well established, simultaneous heart and kidney transplantation has less clear indication and benefits. This uncertainty is also complicated by the competing interest with isolated kidney transplantation candidates who in general wait longer on the waiting list.
Dr. Mahdavi[/caption]
Dr. Sara Mahdavi, PhD
Clinical Scientist and Clinical Instructor
Research Appointment in the Faculty of Medicine
University of Toronto
Toronto, ON
MedicalResearch.com: What is the background for this study?
Response: This was a long-term study spanning 16 years and began with a population of young adults who were medically assessed on a regular basis. It was remarkable to see just how striking the effects of coffee were in the group that had the susceptible genetic variant, what we termed “slow caffeine metabolizers” yet no effect whatsoever in those who did not were termed “fast metabolizers”.
Dr. Balbach[/caption]
Melanie Balbach PhD
Postdoctoral Associate in Pharmacology
Weill Cornell Medicine
MedicalResearch.com: What is the background for this study?
Response: For men, the only two options for birth control currently available are condoms and vasectomy. Additional contraceptive methods are required to more equally distribute the burden of contraception between men and women.
We aim to develop an on-demand contraceptive pill for men where sperm motility and thereby fertility is only blocked for multiple hours. The idea is that men take our contraceptive shortly before intercourse and regain fertility about 24 hours later.